Patients, ≥18 years of age, were eligible for inclusion if they had at least one PAF episode documented by electrocardiogram (ECG) and a properly functioning Vitatron DDDR pacemaker with a bipolar ...

BARCELONA, SPAIN—Cardiac resynchronization therapy (CRT) using an algorithm designed to minimize unnecessary right ventricular pacing is not superior to conventional CRT in patients with systolic ...

Orchestra BioMed’s hypertension treatment is the latest medical device to earn the FDA’s breakthrough designation. The device is an atrio-ventricular interval modulation therapy, meaning it uses a ...

ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...

Seven years after bringing the world's first leadless pacemaker (shown above) to the U.S. market, Medtronic has once again set a new pace in the industry with its next-generation leadless pacemakers.

Implanting a permanent pacemaker after TAVI for prophylactic reasons is not associated with better clinical outcomes when compared with patients with conduction disturbances and a clear indication for ...